Pharmacy Resident MUSC Charleston, South Carolina, United States
Poster Abstract:
Background: Carboplatin is a cytotoxic chemotherapy agent used in a variety of different malignancies.1 It causes intra- and interstrand cross-linking of DNA and DNA-protein leading to cell cycle inhibition and apoptosis.1 A commonly used formula used to calculate the desired dose of carboplatin is the Calvert Equation: Dose (mg) = ((GFR + 25) x target AUC). There are concerns associated with this equation, specifically how to determine renal function (GFR), most commonly estimated using the Cockcroft-Gault equation.2 This equation incorporates a patient's age, serum creatinine (SCr), and weight. There is conflicting guidance regarding the most appropriate weight to use in the calculation (ideal, adjusted, or actual) and the minimum SCr used in certain patient population (e.g., elderly). The purpose of this study is to assess carboplatin dose calculation practices and to determine safety outcomes based on the weight and SCr values used in calculating carboplatin dose in solid tumor patients at an academic medical center.
Objectives: The primary objective is to determine the proportion of initial carboplatin doses calculated using actual, ideal, or adjusted body weight. Secondary objectives include determining the proportion of patients who experienced carboplatin toxicities, dose modification based on weight and SCr, and reason for treatment discontinuation.
Methods: This is a retrospective study looking at adult patients who have received at least one dose of carboplatin at MUSC between January 2023 through June 2023. Patients were excluded if they were part of the gynecologic oncology service, had an unknown tumor type, received investigational carboplatin, or if they were pregnant or a prisoner. Information was collected through electronic medical records, evaluating demographics, chemotherapy regimen information, and health care team documentation.
Results: Data collection and analysis are in process, and results will be reported in detail at the time of presentation.
Conclusions/Discussions: Data collection and analysis are in process, and conclusion/discussion will be reported in detail at the time of presentation.
References (must also be included in final poster): 1. Carboplatin. National Cancer Institute. 2007 Oct 1 [updated 2023 Mar 21, cited 2023 Dec 10]. Available from: Carboplatin - NCI (cancer.gov) 2. Rain MJ. Current Dilemmas in Carboplatin Dosing. Clin Adv Hematol Oncol. 2011 Mar [cited 2023 Dec 10]; 9(3): 237-238. Available from: Current Dilemmas in Carboplatin Dosing – Hematology & Oncology (hematologyandoncology.net)
